Higher concentrations of TKIs such as pazopanib are associated with improved outcomes in advanced RCC. A phase 3 trial failed to show disease-free survival benefit to pazopanib in the adjuvant setting, but improved DFS was seen in patients with higher Ctrough levels, supporting adequate drug exposure for optimal clinical outcome.
http://ift.tt/2FrxgOt
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου